In 1985, ICN and the Eastman-Kodak company launched a six-year, $45 million joint venture to research drugs that slow, halt, or reverse the aging process [REF].
In 1998, the FDA approved Virazole for the treatment of Hepatitis C in conjunction with another medication called interferon [REF].